Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Community-Acquired Bacterial Meningitis in Adults
NEJM 354:44-53, van de Beek,D.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006
Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006
Multiple Sclerosis in Twins From Continental Italy and Sardinia: A Nationwide Study
Ann Neurol 59:27-34, Ristori,G.,et al, 2006
Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006
The Clinical Spectrum of Neuralgic Amyotrophy in 246 cases
Brain 129:438-450, Alfen, N.V. & Baziel, G.M., 2006
MRI T2 Hypointensity of the Dentate Nucleus is Related to Ambulatory Impairment in Multiple Sclerosis
J Neurol Sci 234:17-24, Tjoa,C.W.,et al, 2005
Intractable Hiccup and Nausea With Pariaqueductal Lesions in Neuromyelitis Optica
Neurol 65:1479-1482, Misu,T.,et al, 2005
Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria"
Ann Neurol 58:840-846, Polman,C.H.,et al, 2005
Pregnancy, Delivery, and Birth Outcome in Women with Multiple Sclerosis
Neurol 65:1961-1963, Dahl,J.,et al, 2005
Adrenoleukodystrophy
JAMA 294:3131-3134, Moser,H.W.,et al, 2005
Neurologic and Developmental Disability at Six Years of Age After Extremely Preterm Birth
NEJM 352:9-19, 71, Marlow,N.,et al, 2005
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Is Optic Neuritis More Benign Than Other First Attacks in Multiple Sclerosis?
Ann Neurol 57:210-215, Tintore, M., et al, 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005
Anti-a4 Integrin Therapy for Multiple Sclerosis
Neurol 64:1336-1342, Rice,G.P.A.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Triaging Transient Ischemic Attack and Minor Stroke Patients Using Acute Magnetic Resonance Imaging
Ann Neurol 57:848-854, Coutts,S.B.,et al, 2005
Recommended Standard of Cerebrospial Fluid Analysis in the Diagnosis of Multiple Sclerosis, A Consensus Statement
Arch Neurol 62:865-870, Freedman,M.S.,et al, 2005
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Vagal Nerve Stimulation Effect on Cerebellar Tremor in Multiple Sclerosis
Neurol 65:499, Marrosu,F.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Systemic Mastocytosis: A Potential Neurologic Emergency
Neurol 65:332-333, Boncoraglio,G.B.,et al, 2005
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis
Arch Neurol 62:1362-1365, Alonso,A.,et al, 2005
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
Randomized, Controlled Trial of Cannabis-Based Medicine in Central Pain in Multiple Sclerosis
Neurol 65:812-819,788, Rog,D.J.,et al, 2005
Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke
Stroke 36:1115-1119, Marini,C.,et al, 2005
Overdiagnosis of Multiple Sclerosis and Magnetic Resonance Imaging Criteria
Ann Neurol 58:781-783, Nielsen,J.M.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Multiple Cranial Nerve Palsies
Arch Neurol 62:1714-1717, Keane,J.R., 2005
Whole-Body Hypothermia for Neonates with Hypoxic-Ischemic Encephalopathy
NEJM 353:1574-1584, Shankaran,S.,et al, 2005
Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Diffusion MRI in Multiple Sclerosis
Neurol 65:1526-1532, Rovaris,M.,et al, 2005
Axonal Injury in Early Multiple Sclerosis is Irreversible and Independent of the Short-Term Disease Evolution
Neurol 65:1626-1630, Rovaris,M.,et al, 2005
Unusual Presentation of Central Nervous System Cryptococcal Infection in an Immunocompetent Patient
AJNR 26:2522-2526, Saigal,G.,et al, 2005